We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug
Read MoreHide Full Article
Shares of Plus Therapeutics, Inc. (PSTV - Free Report) were up a staggering 170.1% on March 20 after the company announced that the FDA has conditionally accepted — Reyobiq — as the new proprietary name for PSTV’s lead therapeutic candidate, rhenium Re186 obisbemeda.
Plus Therapeutics’ request for a proprietary name review for Reyobiq must be submitted after the new drug application (NDA) is filed for the candidate.
Per the company, going forward, all communications related to the USAN-adopted and INN-proposed rhenium Re186 obisbemeda generic name will now use the newly accepted proprietary name of Reyobiq.
A novel injectable radiotherapy, Reyobiq (rhenium Re186 obisbemeda), is being specifically developed to deliver highly targeted high-dose radiation in central nervous system tumors, with the potential to reduce risks and improve patient outcomes.
In the past year, shares of Plus Therapeutics have declined 26.2% compared with the industry’s decrease of 6.7%.
Image Source: Zacks Investment Research
Recent Updates on PSTV's Reyobiq
Plus Therapeutics is developing Reyobiq for treating leptomeningeal metastases (“LM”) and recurrent glioblastoma (GBM).
Earlier this month, the FDA granted an Orphan Drug Designation to Reyobiq for the treatment of LM in patients with lung cancer. LM is a rare cancer complication in which the primary cancer spreads to the cerebrospinal fluid and leptomeninges that cover the brain and spinal cord.
Enrollment has been completed in the ReSPECT-LM phase I single-dose escalation study, which will evaluate the safety, tolerability and potential efficacy of intrathecally administered Reyobiq in patients with LM.
PSTV is now gearing up for a phase II single-dose expansion study and a phase I multiple-dose study on Reyobiq for patients with LM.
The company is evaluating Reyobiq in the phase I/II ReSPECT-GBM study for the treatment of recurrent glioblastoma.
In the absence of a marketed product, successful development of Reyobiq remains in key focus for Plus Therapeutics.
PSTV's Zacks Rank & Stocks to Consider
Plus Therapeutics currently carries a Zacks Rank #3 (Hold).
In the past 60 days, estimates for Gilead’s earnings per share have increased from $7.56 to $7.87 for 2025. During the same time, earnings per share estimates for 2026 have increased from $7.76 to $8.27. In the past year, shares of GILD have rallied 45.8%.
GILD’s earnings beat estimates in each of the trailing four quarters, the average surprise being 19.47%.
In the past 60 days, estimates for Dynavax’s earnings per share have increased from 32 cents to 33 cents for 2025. During the same time, earnings per share estimates for 2026 have increased from 49 cents to 57 cents. In the past year, shares of DVAX have rallied 10.8%.
DVAX’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 9.58%.
In the past 60 days, estimates for Arvinas’ loss per share have narrowed from $4.42 to $3.49 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $4.19 to $3.65. In the past year, shares of ARVN have plunged 78.5%.
ARVN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 32.56%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug
Shares of Plus Therapeutics, Inc. (PSTV - Free Report) were up a staggering 170.1% on March 20 after the company announced that the FDA has conditionally accepted — Reyobiq — as the new proprietary name for PSTV’s lead therapeutic candidate, rhenium Re186 obisbemeda.
Plus Therapeutics’ request for a proprietary name review for Reyobiq must be submitted after the new drug application (NDA) is filed for the candidate.
Per the company, going forward, all communications related to the USAN-adopted and INN-proposed rhenium Re186 obisbemeda generic name will now use the newly accepted proprietary name of Reyobiq.
A novel injectable radiotherapy, Reyobiq (rhenium Re186 obisbemeda), is being specifically developed to deliver highly targeted high-dose radiation in central nervous system tumors, with the potential to reduce risks and improve patient outcomes.
In the past year, shares of Plus Therapeutics have declined 26.2% compared with the industry’s decrease of 6.7%.
Image Source: Zacks Investment Research
Recent Updates on PSTV's Reyobiq
Plus Therapeutics is developing Reyobiq for treating leptomeningeal metastases (“LM”) and recurrent glioblastoma (GBM).
Earlier this month, the FDA granted an Orphan Drug Designation to Reyobiq for the treatment of LM in patients with lung cancer. LM is a rare cancer complication in which the primary cancer spreads to the cerebrospinal fluid and leptomeninges that cover the brain and spinal cord.
Enrollment has been completed in the ReSPECT-LM phase I single-dose escalation study, which will evaluate the safety, tolerability and potential efficacy of intrathecally administered Reyobiq in patients with LM.
PSTV is now gearing up for a phase II single-dose expansion study and a phase I multiple-dose study on Reyobiq for patients with LM.
The company is evaluating Reyobiq in the phase I/II ReSPECT-GBM study for the treatment of recurrent glioblastoma.
In the absence of a marketed product, successful development of Reyobiq remains in key focus for Plus Therapeutics.
PSTV's Zacks Rank & Stocks to Consider
Plus Therapeutics currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Gilead Sciences, Inc. (GILD - Free Report) , Dynavax Technologies Corporation (DVAX - Free Report) and Arvinas Inc. (ARVN - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for Gilead’s earnings per share have increased from $7.56 to $7.87 for 2025. During the same time, earnings per share estimates for 2026 have increased from $7.76 to $8.27. In the past year, shares of GILD have rallied 45.8%.
GILD’s earnings beat estimates in each of the trailing four quarters, the average surprise being 19.47%.
In the past 60 days, estimates for Dynavax’s earnings per share have increased from 32 cents to 33 cents for 2025. During the same time, earnings per share estimates for 2026 have increased from 49 cents to 57 cents. In the past year, shares of DVAX have rallied 10.8%.
DVAX’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 9.58%.
In the past 60 days, estimates for Arvinas’ loss per share have narrowed from $4.42 to $3.49 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $4.19 to $3.65. In the past year, shares of ARVN have plunged 78.5%.
ARVN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 32.56%.